Please use this identifier to cite or link to this item:
Title: 12-month randomised controlled trial of ginseng extract for moderate COPD.
Austin Authors: Shergis, Johannah Linda;Thien, Francis;Worsnop, Christopher J ;Lin, Lin;Zhang, Anthony L;Wu, Lei;Chen, Yuanbin;Xu, Yinji;Langton, David;Da Costa, Cliff;Fong, Harry;Wu, Darong;Story, David;Xue, Charlie C
Affiliation: Guangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China
School of Science, RMIT University, Melbourne, Victoria, Australia
Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA
The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China
School of Health and Biomedical Sciences, RMIT University, Melbourne, Victoria, Australia
Department of Respiratory Medicine, Eastern Health, Box Hill, Victoria, Australia
Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia
Department of Thoracic Medicine, Frankston Hospital, Frankston, Victoria, Australia
Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Victoria, Australia
Issue Date: Jun-2019 2019-06
Publication information: Thorax 2019; 74(6): 539-545
Abstract: Panax ginseng (ginseng) is a therapeutic herb which might be beneficial in COPD. The study investigated if ginseng, compared with placebo, is effective and safe for people with moderate COPD. This multicentre, randomised, double-blind, placebo-controlled trial compared 24 weeks of ginseng capsules (100 mg twice daily) with placebo. Participants were followed up for a further 24 weeks. Participants were aged 40 years and over and had airflow limitation in the moderate (Global Initiative for Chronic Obstructive Lung Disease 2) COPD range. The coprimary endpoints were the St George's Respiratory Questionnaire, the COPD Assessment Test and the Short Form Health Survey. Secondary outcomes included lung function, exacerbation rate and use of relief medication. 168 participants were randomised 1:1 from five centres in Australia and China. Baseline characteristics were balanced between groups. There were no significant differences between ginseng and placebo, with overall results improving in both groups. Ginseng seemed safe for, and well tolerated by, people with COPD. There was no significant difference in improvement in health-related quality of life (primary outcome) between the ginseng and placebo groups. ACTRN12610000768099.
DOI: 10.1136/thoraxjnl-2018-212665
Journal: Thorax
PubMed URL: 30940771
Type: Journal Article
Subjects: chronic obstructive pulmonary disease
quality of life
randomised controlled trial
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Feb 2, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.